268 related articles for article (PubMed ID: 21765463)
1. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
[TBL] [Abstract][Full Text] [Related]
2. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
3. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
4. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.
Saha MN; Jiang H; Mukai A; Chang H
Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
7. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
10. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha.
Lee YM; Lim JH; Chun YS; Moon HE; Lee MK; Huang LE; Park JW
Carcinogenesis; 2009 Oct; 30(10):1768-75. PubMed ID: 19696166
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia.
Yang J; Ahmed A; Poon E; Perusinghe N; de Haven Brandon A; Box G; Valenti M; Eccles S; Rouschop K; Wouters B; Ashcroft M
Mol Cell Biol; 2009 Apr; 29(8):2243-53. PubMed ID: 19223463
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
[TBL] [Abstract][Full Text] [Related]
13. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
15. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
[TBL] [Abstract][Full Text] [Related]
16. Chk2 mediates RITA-induced apoptosis.
de Lange J; Verlaan-de Vries M; Teunisse AF; Jochemsen AG
Cell Death Differ; 2012 Jun; 19(6):980-9. PubMed ID: 22158418
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
[TBL] [Abstract][Full Text] [Related]
18. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
[TBL] [Abstract][Full Text] [Related]
19. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.
Merkel CA; da Silva Soares RB; de Carvalho AC; Zanatta DB; Bajgelman MC; Fratini P; Costanzi-Strauss E; Strauss BE
BMC Cancer; 2010 Jun; 10():316. PubMed ID: 20569441
[TBL] [Abstract][Full Text] [Related]
20. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
